505082-91-7

Basic information

• Product Name: 6-(2-Fluorophenyl)-nicotinic acid
• Synonyms: 6-(2-fluorophenyl)-3-Pyridinecarboxylic acid
• CAS NO: 505082-91-7
• Molecular Formula: C₁₂H₈FNO₂
• Molecular Weight: 217.2
• Mol File: 505082-91-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6-(2-Fluorophenyl)-nicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2-Fluorophenyl)-nicotinic acid(505082-91-7)
• EPA Substance Registry System: 6-(2-Fluorophenyl)-nicotinic acid(505082-91-7)

Safety Data

• Hazardous Substances Data: 505082-91-7(Hazardous Substances Data)

Usage

General Description

. 6-(2-Fluorophenyl)-nicotinic acid is a chemical compound with the molecular formula C12H8FNO2. It is a derivative of nicotinic acid and contains a fluorine-substituted phenyl group. 6-(2-Fluorophenyl)-nicotinic acid is commonly used in pharmaceutical research and drug development due to its potential as a therapeutic agent. It has been studied for its possible anti-inflammatory and analgesic properties, as well as its potential use in treating conditions such as cancer and neurological disorders. Additionally, 6-(2-Fluorophenyl)-nicotinic acid has been investigated for its role in modulating certain cellular signaling pathways, making it of interest for further research in the fields of biochemistry and pharmacology.

Upstream product

• 6311-35-9 6-bromonicotinic acid 
• 1993-03-9 o-fluorophenylboronic acid 
• 1033844-92-6 tert-butyl 6-(2-fluorophenyl)nicotinate 

Downstream Products

• 1033844-11-9 6-(2-fluorophenyl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]nicotinamide 
• 582324-65-0 C₂₁H₁₄FN₃O 

Relevant articles and documents

Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models

Activation of prostanoid EP2 receptor exacerbates neuroinflammatory and neurodegenerative pathology in central nervous system diseases such as epilepsy, Alzheimer's disease, and cerebral aneurysms. A selective and brain-permeable EP2 antagonist will be useful to attenuate the inflammatory consequences of EP2 activation and to reduce the severity of these chronic diseases. We recently developed a brain-permeable EP2 antagonist 1 (TG6-10-1), which displayed anti-inflammatory and neuroprotective actions in rodent models of status epilepticus. However, this compound exhibited moderate selectivity to EP2, a short plasma half-life in rodents (1.7 h) and low aqueous solubility (27 μM), limiting its use in animal models of chronic disease. With lead-optimization studies, we have developed several novel EP2 antagonists with improved water solubility, brain penetration, high EP2 potency, and selectivity. These novel inhibitors suppress inflammatory gene expression induced by EP2 receptor activation in a microglial cell line, reinforcing the use of EP2 antagonists as anti-inflammatory agents.

Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1

6-Phenylnicotinamide (2) was previously identified as a potent TRPV1 antagonist with activity in an in vivo model of inflammatory pain. Optimization of this lead through modification of both the biaryl and heteroaryl components has resulted in the discovery of 6-(4-fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide (32; SB-782443) which possesses an excellent overall profile and has been progressed into pre-clinical development.